Cognivue Names Paul W. Estes as President— Promotion of Company Veteran Reflects Neuroscience Technology Developer’s Next Evolutionary Stage

ROCHESTER, N.Y. (April 22, 2024)—Neuroscience technology innovator Cognivue, Inc. announced today that Paul W. Estes has been promoted to president, ushering in the company’s next stage of market evolution. He will guide the executive leadership team and oversee the company’s technology roadmap planning, new product expansion, partnership relations, sales, and staffing.

His appointment comes after 15 years of serving in increasingly senior positions with Cognivue. Estes joined the company in 2009, helping conceive and develop Cognivue® technology, then played integral roles in its de novo 510(k) clearance from the U.S. Food and Drug Administration and subsequent commercialization. Most recently, he was Cognivue’s chief operating officer.

Estes succeeds Tom O’Neil, who left the company for a non-competitive leadership role in the healthcare infrastructure sector.

“Cognivue is headed into its next chapter of success, making it an even greater privilege to lead so many incredibly talented people throughout the company. Cognivue has several exciting developments ahead, such as the full-scale launch of our FDA-cleared next-generation technologies and continued participation in the groundbreaking Bio-Hermes clinical study with the Global Alzheimer’s Platform,” said Estes. “We owe Tom a debt of gratitude for his contributions to Cognivue over the last six years. I plan to build on that momentum, with more growth to come for the benefit of our employees, partners, customers, and patients.”

About Cognivue, Inc.

Cognivue, Inc. is a world-class neuroscience company focusing on cognitive health with the world’s first FDA-cleared computerized test of cognitive function. The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on information processing by testing key cognitive domains. The technology significantly improves the ability of healthcare providers to implement a personalized assessment of cognitive function in a wide variety of care settings. The company is elevating the gold standard of cognitive health assessment and empowering the healthcare community to monitor, identify, and act early on cognitive health concerns. For more information, call (585) 203-1969 or visit

Media Contact:
Carson Daniels

McDougall Communications for Cognivue, Inc. or +1.315.427.6394